Turnaround delayed but hope remains intact
20/03/23 -"Our positive recommendation on UCB is reiterated, backed by the strong growth potential of its newer crop of drugs and late-stage pipeline, and eventual profitability/cashflow improvements (even ..."
Pages
52
Language
English
Published on
20/03/23
You may also be interested by these reports :
13/05/24
Lundbeck’s 2023 profitability fell short of our expectations as, despite some yoy improvement, margins were under pressure from higher SG&A related ...
10/05/24
Novonesis reported largely in-line Q1 24 numbers. Q1 24 revenue was up 45% on a pro-forma basis, helped by strong performances in the key segments of ...
08/05/24
Sandoz is moving ahead well with two crucial aspects of its medium-term sales and profitability goals: 1/ a strong performance from Biosimilars and ...
07/05/24
Q1 sales missed the consensus estimates, although the CER growth was largely in line with the firm’s full-year outlook. Biosimilars were the main ...